Testosterone Undecanoate
FDA-approved product (injectable, intramuscular), marketed as Aveed, Jatenzo, Kyzatrex and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Hypogonadism
- Hypogonadotropic hypogonadism
- Klinefelter's syndrome
- Neoplasm
- Orchitis
- Physiological sexual disorder
- Sexual dysfunction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- 3-oxoandrosten (4) derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Testosterone Undecanoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency
NCT07512323 · start 2026-08-01
Registered record
- Registry ID
- NCT07512323
- Conditions
- Frail Elderly Patients; Hypogonadal Males; Testosterone Replacement Therapy; Falls (Accidents) in Old Age
- Interventions
- Nebido (Testosterone Undecanoate)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-08-01
- Completion
- 2030-09-30
- Enrolment
- 96
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFrail Elderly Patients; Hypogonadal Males; Testosterone Replacement Therapy; Falls (Accidents) in Old AgeInterventionNebido (Testosterone Undecanoate)PhasePhase 2Registry statusNot yet recruitingTestosterone-induced Muscle Memory and Underlying Mechanisms
NCT06188767 · start 2025-04-01
Registered record
- Registry ID
- NCT06188767
- Conditions
- Skeletal Muscle Physiology
- Interventions
- Testosterone Undecanoate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2025-04-01
- Completion
- 2028-12-01
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSkeletal Muscle PhysiologyInterventionTestosterone UndecanoatePhaseNot applicableRegistry statusRecruitingAn Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD
NCT06082817 · start 2025-01-01
Registered record
- Registry ID
- NCT06082817
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Oral Testosterone Undecanoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2025-01-01
- Completion
- 2025-12-31
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypoactive Sexual Desire DisorderInterventionOral Testosterone UndecanoatePhasePhase 2Registry statusNot yet recruitingComparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration
NCT06393634 · start 2024-11-27
Registered record
- Registry ID
- NCT06393634
- Conditions
- Healthy
- Interventions
- Testosterone injection; Testosterone gel; Testosterone Oral
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2024-11-27
- Completion
- 2024-11-27
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionTestosterone injection; Testosterone gel; Testosterone OralPhaseEarly phase 1Registry statusCompletedSafety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
NCT05081193 · start 2022-03-07
Registered record
- Registry ID
- NCT05081193
- Conditions
- Prostate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
- Interventions
- Testosterone Undecanoate; Enzalutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2022-03-07
- Completion
- 2025-08-04
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate CancerInterventionTestosterone Undecanoate; EnzalutamidePhasePhase 2Registry statusCompletedTestosterone Undecanoate Replacement Therapy in Boys With Pubertal Delay or Confirmed Hypogonadism
NCT05541172 · start 2022-03-01
Registered record
- Registry ID
- NCT05541172
- Conditions
- Delayed Puberty; Male Hypogonadism
- Interventions
- Testosterone Undecanoate
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2022-03-01
- Completion
- 2025-12-31
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDelayed Puberty; Male HypogonadismInterventionTestosterone UndecanoatePhaseNot recordedRegistry statusUnknownPain Alleviation With Testosterone in Opioid-Induced Hypogonadism
NCT04798469 · start 2022-01-10
Registered record
- Registry ID
- NCT04798469
- Conditions
- Opioid Use; Pain; Hypogonadism, Male
- Interventions
- Testosterone Undecanoate 250 MG/ML; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2022-01-10
- Completion
- 2027-12-30
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid Use; Pain; Hypogonadism, MaleInterventionTestosterone Undecanoate 250 MG/ML; PlaceboPhasePhase 2Registry statusRecruitingPatient Satisfaction After Switching to Oral Testosterone Undecanoate
NCT04983940 · start 2021-06-18
Registered record
- Registry ID
- NCT04983940
- Conditions
- Testosterone Deficiency
- Interventions
- Jatenzo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2021-06-18
- Completion
- 2023-04-06
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTestosterone DeficiencyInterventionJatenzoPhasePhase 4Registry statusCompletedTestosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
NCT04049331 · start 2021-03-22
Registered record
- Registry ID
- NCT04049331
- Conditions
- Hypogonadism, Male; Fatigue Syndrome, Chronic
- Interventions
- Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2021-03-22
- Completion
- 2027-01-30
- Enrolment
- 240
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism, Male; Fatigue Syndrome, ChronicInterventionTestosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]; placeboPhasePhase 2Registry statusRecruitingA Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
NCT04685993 · start 2020-11-11
Registered record
- Registry ID
- NCT04685993
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- LPCN 1144
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2020-11-11
- Completion
- 2022-03-01
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNASH - Nonalcoholic SteatohepatitisInterventionLPCN 1144PhasePhase 2Registry statusCompletedThe Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
NCT06489457 · start 2020-09-20
Registered record
- Registry ID
- NCT06489457
- Conditions
- Type 2 Diabetes Mellitus; Obesity; Functional Hypogonadism
- Interventions
- Semaglutide; Testosterone Undecanoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2020-09-20
- Completion
- 2023-06-30
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionType 2 Diabetes Mellitus; Obesity; Functional HypogonadismInterventionSemaglutide; Testosterone UndecanoatePhasePhase 3Registry statusCompletedA Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
NCT04456296 · start 2020-06-30
Registered record
- Registry ID
- NCT04456296
- Conditions
- Hypogonadism; Hypogonadism, Male; Hypogonadotropic Hypogonadism
- Interventions
- Aveed Injectable Product; Fortesta; Testim
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2020-06-30
- Completion
- 2023-07-12
- Enrolment
- 673
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism; Hypogonadism, Male; Hypogonadotropic HypogonadismInterventionAveed Injectable Product; Fortesta; TestimPhasePhase 4Registry statusCompletedTrial of Testosterone Undecanoate for Optimizing Performance During Military Operations
NCT04120363 · start 2019-09-23
Registered record
- Registry ID
- NCT04120363
- Conditions
- Caloric Restriction; Exercise; Sleep
- Interventions
- Testosterone Undecanoate; Sesame Oil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2019-09-23
- Completion
- 2021-07-08
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCaloric Restriction; Exercise; SleepInterventionTestosterone Undecanoate; Sesame OilPhasePhase 4Registry statusCompletedMultimodality Intervention for Function and Metabolism in SCI
NCT03576001 · start 2019-08-23
Registered record
- Registry ID
- NCT03576001
- Conditions
- Spinal Cord Injuries
- Interventions
- Testosterone Undecanoate; hybrid exercise
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2019-08-23
- Completion
- 2025-03-30
- Enrolment
- 84
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpinal Cord InjuriesInterventionTestosterone Undecanoate; hybrid exercisePhasePhase 2Registry statusCompletedEfficacy and Safety of Testosterone Therapy in Improving Sarcopenia in Men With Cirrhosis.
NCT03995251 · start 2019-07-04
Registered record
- Registry ID
- NCT03995251
- Conditions
- Liver Cirrhosis
- Interventions
- Testosterone Supplementation; Standard Medical Treatment; Exercise
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2019-07-04
- Completion
- 2020-06-30
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLiver CirrhosisInterventionTestosterone Supplementation; Standard Medical Treatment; ExercisePhaseNot applicableRegistry statusUnknown